Olaparib in the maintenance treatment of platinum-sensitive relapse of BRCA mutant ovarian cancer in routine clinical practice: first results of observational study in Russian patients

Cover Page

Cite item

Full Text

Abstract

Background and aims. There is no data on olaparib efficacy and safety in Russian routine clinical practice. Methods. We analysed the 30 consecutive patients who received maintenance olaparib treatment for platinum-sensitive relapse (PSR) of ovarian or fallopian tube cancer in Russian Cancer Centers. Patients were prescribed olaparib capsules 400 mg twice daily. Radiographic assessments were done every 8 weeks. Patient characteristics. Age median 55 (range 39-68); 26 (86,6%) patients had gBRCA1, 2 (6,6%) patients had sBRCA1, 2 (6,6%) patients had gBRCA2. Number of relapse: median 1 (range 1-10), number of lines of chemotherapy: median 2 (range 2-11). Last regimen of chemotherapy: taxane + platinum (± bevacizumab) 90% (27/30), platinum monotherapy 10% (3/30). Best response to the last chemotherapy complete response 43,3% (13/30), partial response 36,7% (11/30), stable disease 20% (6/30). Results. Median follow-up in 13 CR patients was 12 mos. 1 CR patient progressed after 9 mos of maintenance olaparib. Median follow-up in 11 PR patients was 7 mos. 3 PR patients achieved CR on olaparib. 1 PR patient progressed after 6 mos of olaparib maintenance. Median follow-up in SD patients was 12 mos. 1 SD patient achieved PR on olaparib, there were no progressions. 10 (30%) patients had adverse events (AEs). 1 patient had grade 3 AE and 2 patients had AEs leading to dose reduction. There were no grade 4 AEs. Conclusions. Olaparib is safe and effective maintenance treatment of PSR ovarian cancer in routine clinical settings.

About the authors

E V Artamonova

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

Email: artamonovae@mail.ru
д-р мед. наук, зав. отд-нием химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

E I Kovalenko

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

канд. мед. наук, науч. сотр. отд-ния амбулаторной химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

A V Snegovoy

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

д-р мед. наук, зав. отд-нием амбулаторной химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

A A Aksarin

Surgut District Clinical Hospital

канд. мед. наук, рук. онкологического центра 628408, Russian Federation, Surgut, ul. Energetikov, d. 14

T A Anciferova

City Polyclinic №195 of the Department of Health of Moscow

зав. отд-нием онкологии 121614, Russian Federation, Moscow, ul. Krylatskie holmy, d. 51

A V Belonogov

Moscow City Oncological Hospital №62 of the Department of Health of Moscow

канд. мед. наук, зав. дневным стационаром №1 143423, Russian Federation, Moscow obl., pos. Istra, d. 27, str. 1-26

E V Bilan

District Clinical Hospital

зав. окружным онкологическим центром , г. Ханты-Мансийск, гл. внештатный специалист-онколог ДЗ ХМАО-Югры 628012, Russian Federation, Khanty-Mansiysk, ul. Kalinina, d. 40

S N Bilenko

City Polyclinic №218 of the Department of Health of Moscow

врач-онколог 127642, Russian Federation, Moscow, pr. Shokalskogo, d. 8

I M Varvus

City Polyclinic №218 of the Department of Health of Moscow

врач-онколог 127642, Russian Federation, Moscow, pr. Shokalskogo, d. 8

E A Gorkovenko

Elektrostal City Clinical Hospital

врач-гинеколог 144000, Russian Federation, Moscow obl., Elektrostal, ul. Pushkina, d. 3

R F Enikeev

Republican Clinical Oncologic Dispensary of the Ministry of Health of the Republic of Tatarstan

канд. мед. наук, врач-онколог 420029, Russian Federation, Kazan, ul. Sibirskiy trakt, d. 29

A M Ermolaeva

Nizhny Novgorod Regional Clinical Oncologic Dispensary

зав. химиотерапевтическим отд-нием 603093, Russian Federation, Nizhny Novgorod, ul. Delovaia, d. 11/1

L V Kramskaya

D.D.Pletnev City Clinical Hospital of the Department of Health of Moscow

зав. 3-м онкологическим отд-нием 105077, Russian Federation, Moscow, ul. 11-ia Parkovaia, d. 32

I B Kononenko

N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation

канд. мед. наук, ст. науч. сотр. отд-ния амбулаторной химиотерапии 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

A P Pechenyy

Orel Oncologic Dispensary

канд. мед. наук, врач-онколог, поликлиническое отд-ние 302020, Russian Federation, Orel, per. Ippodromnii, d. 2

S Z Safina

Republican Clinical Oncologic Dispensary of the Ministry of Health of the Republic of Tatarstan

канд. мед. наук, зав. отд. химиотерапии 420029, Russian Federation, Kazan, ul. Sibirskiy trakt, d. 29

T V Chupriyanova

Perm Regional Oncologic Dispensary

зам. глав. врача 614066, Russian Federation, Perm, ul. Baumana, d. 15

G G Chuhua

Republican Clinical Oncologic Dispensary of the Ministry of Health of the Republic of Tatarstan

врач-онколог, отд-ние химиотерапии №3 420029, Russian Federation, Kazan, ul. Sibirskiy trakt, d. 29

A I Shemyakina

Noginsk Central District Hospital

врач-онкогинеколог 142400, Russian Federation, Moscow obl., Noginsk, Komsomolskaia ul., d. 59

E V Shikina

Moscow Regional Clinical Oncologic Dispensary

канд. мед. наук, зав. химиотерапевтическим отд-нием дневного стационара 143900, Russian Federation, Moscow obl., Balashiha, ul. Karbysheva, d. 6

References

  1. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf (GLOBOCAN 2008 (IARC). Section of Cancer Information (6/3/2011); p. 3-7.
  2. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М., 2017.
  3. Press J.Z, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17.
  4. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
  5. Любченко Л.Н., Бартенева Е.И., Абрамов И.С. и др. Наследственный рак молочной железы и яичников. Злокачественные опухоли. 2013; 2: 53-61.
  6. Daniels M.S, Babb S.A, King R.H et al. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. J Clin Oncol 2014; 32: 1249-55.
  7. Hamel N et al. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2011; 19 (3): 300-6.
  8. Patel J.N. Differences in pharmacology, toxicities key to clinical use of PARP inhibitors. HemOnc Today, March 10, 2018.
  9. Farmer H, McCabe N, Lord C.J et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
  10. Bryant H.E, Schultz N, Thomas H.D et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
  11. Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916-25.
  12. Fong P.C, Boss D.S, Yap T.A et al. Inhibitions of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Eng J Med 2009. DOI: 10.1056;NEJMoa0900212
  13. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-92.
  14. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852-61.
  15. Ledermann J.A, Harter P, Gourley C et al. Overall sur-vival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: an interim analysis. J Clin Oncol 2016; 34 (Suppl. 15): abst 5501.
  16. Lederman J.A, Harter Ph, Gourley Ch et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet 2016; 16 (11): 1579-89.
  17. Pujade-Lauraine E, Lederman J.A, Selle F et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 2017; 18 (9): 1274-84.
  18. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v4.02. 2009. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
  19. Therasse P, Arbuck S.G, Eisenhauer E.A et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies